colon carcinogenesis and is detectable in ϳ85% of colon carcinomas (10, 11) . Tumors that express high levels of COX-2 are associated with larger tumor size, increased stage of disease, and lower survival (12) . The mechanisms by which COX-2 expression could contribute to colon cancer progression is uncertain but include enhancement of cell proliferation, reduction in cell death (apoptosis), or induction of mutations leading to malignancy. We are investigating the possibility that COX-2 expression leads to increased DNA damage and mutation. The likely mediator of DNA damage is malondialdehyde (MDA), a product of the breakdown of PGH 2 (Fig. 1) .
MDA is carcinogenic in rats, mutagenic in bacterial and mammalian cells, and reacts with DNA to form adducts with guanine, adenine, and cytosine (13) (14) (15) (16) (17) (18) (19) (20) . The breakdown of PGH 2 to hydroxyheptadecatrienoic acid (HHT) and MDA occurs spontaneously or can be catalyzed by ferrous ion or heme ( Fig. 1) (21, 22) . In addition, several enzymes have been found to have an auxiliary "HHT/MDA synthase" activity. Thromboxane synthase converts PGH 2 to thromboxane A 2 , HHT, and MDA in a 1:1:1 ratio (22) (23) (24) . Prostacyclin synthase converts PGH 2 to prostacyclin but produces exclusively MDA and the C 17 hydroxy acid from PGH 1 , a metabolite of eicosatrienoic acid (22, 25) . Both thromboxane synthase (CYP5) and prostacyclin synthase (CYP8) belong to the cytochrome P450 superfamily (also termed heme-thiolate protein P450 by the Enzyme Commission, EC 1.14.14.1), which suggests that such a reaction may be general to other cytochromes P450. Hecker and Ullrich (22) have shown that both prokaryotic P450 CAM from Pseudomonas putida and rat liver microsomes convert PGH 2 to primarily HHT, but other mammalian P450s have not been studied.
It is increasingly recognized that expression of xenobioticmetabolizing P450s is a characteristic of extrahepatic malignancies (26 -36) . Just as COX-2 is overexpressed in both colorectal adenomas and carcinomas, P450 1A and 3A are both are overexpressed in human colonic adenomas and carcinomas as determined by immunohistochemistry (37) . In addition, it has been found that chronic alcohol consumption, a known risk factor for colorectal cancer, induces P450s 2E1 and 2C7 in the colon of rats (38) . Finally, 2,3,7,8-tetrachlorodibenzo-p-dioxin, a co-inducer of P450 1A1 and COX-2 (39), has been shown to shift the prostaglandin profile to increased HHT in wild type Hepa-1 cells but not in a cell line with mutant P450 1A1 (40) .
Given the co-expression of COX-2-and xenobiotic-metabolizing P450s in human colon cancers, we studied the ability of several well characterized P450s to convert PGH 2 to HHT and the known endogenous mutagen, MDA. We find that a wide variety of P450s from different species are efficient HHT/MDA synthases when PGH 2 is the substrate. These findings suggest new roles for COX-2 and P450s as co-conspirators in compromising genome integrity by accelerating DNA damage via MDA.
EXPERIMENTAL PROCEDURES
Chemicals-Triphenylphosphine, sodium dithionite, and pyridine were purchased from Aldrich. Beef liver catalase was purchased from Roche Molecular Biochemicals. PGD 2 , PGE 2 , PGF 2␣ , U-44069, and U-46619 were purchased from Cayman Chemical Co. (Ann Arbor, MI). High pressure liquid chromatography grade solvents, phenol, K 2 HPO 4 , and KH 2 PO 4 were purchased from Fisher. Ketoconazole, clotrimazole, hemin, bovine hemoglobin, Tris-HCl, K 3 Fe(CN) 6 , MgSO 4 , Na 2 CO 3 , and silicic acid were purchased from Sigma. Oxygen gas was purchased from Specialty Gases (Louisville, KY).
Preparation of Endoperoxide-[1-
14 C]PGH 2 (0.5 Ci/mol) was prepared following published methods (41, 42) . Briefly, microsomes were isolated from 30 -40 g of ram seminal vesicles (Oxford Biomedical Research, Inc., Oxford, MI) and stored at Ϫ80°C until use. Microsomes were resuspended in 15 ml of 100 mM sodium phosphate, pH 7.8, mixed with 85 ml of oxygen-saturated Tris-HCl buffer, pH 7.8, containing 500 M phenol, and incubated at 25°C. After 2 min, 10 -20 mg of arachidonic acid (20 mg) (Nu Chek Prep, Elysian, MN) containing a tracer amount (0.5 Ci/mol) of [1- 14 C]arachidonic acid (NEN Life Science Products) dissolved in 0.5 ml of ethanol was added. After 2 min, 350 l of 6 N HCl was added and rapidly extracted twice with diethyl ether chilled to 4°C. The combined ether layers were dried over 10 g of MgSO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was dissolved in hexane/diethyl ether (80:20) and purified by activated silicic acid chromatography (60 -200 mesh). Fractions were pooled, evaporated to dryness under reduced pressure, and stored in dry acetone or acetonitrile at Ϫ20°C. PGH 2 preparations were routinely 85-90% pure as characterized by TLC (described below), and the material that co-eluted with PGH 2 could be completely converted to PGF 2␣ by 40 mM triphenylphosphine.
Preparation of Human Liver Microsomes and P450s-Human liver microsomes were prepared as described by Guengerich (43) and determined to contain high levels of P450 3A4 by immunoblot analysis. Membranes from Escherichia coli expressing human P450 3A4 were prepared as described by Gillam et al. (44) . The following human P450s were purified from bacterial expression systems according to published methods as follows: 3A4 (44), 1A2 (45) , and 2E1 (46) . Rat 1A2, rat 2B1, and rabbit 1A2 were purified from liver (45, 47, 48) . Human cytochrome b 5 was prepared as described by Shimada et al. (49) .
Determination of Heme and P450 Concentrations-Heme concentrations were determined by the pyridine hemochrome assay using ⑀ ⌬(556 -540) ϭ 20.7 mM Ϫ1 ⅐cm Ϫ1 (50, 51) . P450 concentrations were determined by measuring the absorbance at 450 nm following dithionite reduction in the presence of carbon monoxide (52) .
TLC Assay for HHT/MDA Synthase Activity-Enzyme or hemin solutions were prepared in 450 l of 50 mM potassium phosphate, pH 7.4. For inhibition experiments, clotrimazole or ketoconazole was added in 4.5 l of ethanol to human liver microsomes (0.7 M P450) in 450 l of 50 mM potassium phosphate, pH 7.4, and preincubated for 5 min at room temperature. [1- 14 C]PGH 2 (50 M) was added in 9 l of acetone and incubated at room temperature for 3 min. Reactions were terminated by addition of 400 l of 40 mM triphenylphosphine in diethyl ether, methanol, 1 M citric acid (80:12:2.8, v/v). The organic phase was spotted on silica gel thin layer plates (J. T. Baker Inc.) and developed with water-saturated ethyl acetate/isooctane/glacial acetic acid (90:50: 20, v/v/v). Radiolabeled products were quantitated with a radioactivity scanner (Bioscan, Inc. Washington, D. C.).
Mass Spectrometry-Rabbit P450 1A2 (1 M) and PGH 2 (84 M) were incubated in 450 l of 50 mM potassium phosphate, pH 7.4, at room temperature for 3 min, and the products were extracted and reduced with triphenylphosphine as described above. The organic layer was evaporated under a stream of nitrogen and redissolved in 50 l of methanol for liquid chromatography/mass spectrometry studies and 100 l of water/methanol/glacial acetic acid (50:50:1, v/v/v) for direct flow injection/tandem mass spectrometry.
High performance liquid chromatography/negative ion electrospray ionization/selected ion monitoring-mass spectrometry conditions were as follows: 5-l injections, 150 ϫ 2.1 mm inner diameter, 5-m Zorbax® C8 column (Hewlett-Packard); solvent A, nanopure water; solvent B, acetonitrile; flow rate, 0.2 ml/min; linear gradient from 40% solvent B to 65% solvent B in 15 min; Finnigan TSQ 7000 triple-quadrupole mass spectrometer equipped with an electrospray ionization source operated in the negative ion mode with nitrogen sheath gas (70 pounds/square inch); spray voltage, 3. For negative ion electrospray ionization/tandem mass spectrometry, the sample was introduced by direct flow injection at 30 l/min into the electrospray ionization source. The collision gas in the second quadrupole was argon (Liquid Air, Walnut Creek, CA) at 2.6 millitorr with a collision energy of 18 eV. The daughter fragment ions of m/z 279 were analyzed by the third quadrupole with scan time of 1.5 s for 1 min.
Spectrophotometric Assay for MDA-Purified P450s in 200 l of 50 mM potassium phosphate, pH 7.4 (or 300 mM potassium phosphate, pH 7.4 for CYP1A2 and CYP2E1), were incubated at 25°C with 50 M PGH 2 added in 4.5 l of acetonitrile. MDA formation over time was measured by absorbance at 268 nm using a Hewlett-Packard 8452A diode array spectrophotometer (53) . Initial rates were determined by linear fitting of the first 10 -20 s. Activities were determined from the slope of a linear fit to triplicate measurement of initial rates at four different P450 concentrations. For boiled controls, enzyme solutions were heated for 10 min at 100°C and then equilibrated to 25°C before addition of PGH 2 .
P450 Binding Assays-An OLIS DW-2 split beam UV-visible spectrophotometer (Aminco) was blanked with 150 l of 2 M P450 in 300 mM potassium phosphate buffer, pH 7.4, in both reference and sample quartz microcuvettes. U-44069 or U-46619 from a stock of 6 mg/ml in 10 mM Na 2 CO 3 was added to the sample cuvette, and an equal volume of 10 mM Na 2 CO 3 was added to the reference cuvette. The difference spectrum was recorded between 350 and 500 nm. Relative binding at each concentration of ligand was calculated by subtracting minima from maxima, and spectral dissociation constants (K s ) were calculated with Prism 2.0b software (GraphPad Software Inc., San Diego, CA).
RESULTS

Conversion of PGH 2 to HHT by Human Liver Microsomes-
In order to study the conversion of PGH 2 to HHT and MDA, a radiometric thin layer chromatography assay was devised. Radiolabeled PGH 2 was prepared biosynthetically from incubation of [1- 14 C]arachidonic acid with ram seminal vesicle microsomes according to published procedures (21, 41, 42) . PGH 2 preparations were routinely 85-90% radiochemically pure as determined by TLC (Fig. 2a) . PGH 2 is unstable in aqueous solution and during workup. This instability could complicate interpretation of experiments because any unreacted PGH 2 could artifactually generate HHT after incubation with enzymes but before analysis by TLC. Therefore, we terminated incubations by organic extraction with solvent containing a small amount of the mild reducing agent, triphenylphosphine. This reagent reduces any unreacted PGH 2 to the more stable PGF 2␣ without affecting HHT, PGE 2 , or PGD 2 . Thus, HHT could only arise during incubation with enzymes as illustrated in Fig. 2 . An additional advantage of using triphenylphosphine is that it converts the non-polar PGH 2 to the more polar PGF 2␣ avoiding co-migration with the relatively non-polar HHT. Under our assay conditions, PGH 2 decomposed slightly in buffer alone but was almost entirely converted to a non-polar metabolite by human liver microsomes that we suspected to be HHT (Fig. 2, b and c) . The polar product in Fig. 2c co-migrated with a PGE 2 standard.
Identification of HHT/MDA Synthase Activity-The TLC assay was used to characterize the HHT/MDA synthase activity of human liver microsomes. The percentage of radiolabled PGH 2 that was converted to HHT following incubation with varying amounts of human liver microsomes is plotted in Fig.  3a . Human liver microsomes clearly stimulate conversion of PGH 2 to HHT in a dose-dependent manner. To test whether it was a P450 component of the liver microsomes responsible for this activity, varying concentrations of P450 inhibitors were preincubated with the microsomes. Because these human liver microsomes are known to contain a high amount of P450 3A4, we used the imidazole antimycotic P450 inhibitors ketoconazole and clotrimazole which are both potent inhibitors of P450 3A4 (54) . Both prevented microsomal conversion of PGH 2 to HHT with IC 50 values of 1 and 0.4 M, respectively (Fig. 3b) . The fact that these IC 50 values are higher than reported K i values can be readily explained by inhibitor depletion by the relatively high enzyme concentrations used in these assays (54) .
To demonstrate that the P450 component of the microsomes is sufficient for HHT/MDA synthase activity, we expressed recombinant human P450 3A4 in E. coli and assayed an equivalent amount of total heme of the isolated membranes for HHT production (Fig. 4) . At the same total heme concentration (1 M), P450 3A4 expressing bacterial membranes converted PGH 2 to HHT nearly as well as human liver microsomes. Likewise, human P450 3A4 (1 M) purified from the bacterial membranes efficiently produced HHT (Fig. 4) . Purified human P450 2E1 and rabbit P450 1A2 also converted PGH 2 to HHT in the TLC assay (data not shown). Consistent with the findings of Hecker and co-workers (22, 53) , hemin alone produced a statistically significant increase above buffer (p ϭ 0.012), but the same heme concentration of human liver microsomes produced 15-fold more HHT. Other heme proteins, namely cytochrome b 5 , catalase, and hemoglobin did not convert PGH 2 to HHT beyond what was observed with an equivalent concentration of hemin alone (Fig. 4) . Therefore, the conversion of PGH 2 to HHT and MDA is dependent on heme in the context of the P450 protein.
Characterization of HHT-To characterize structurally the reaction products in a cleaner system, PGH 2 was incubated with purified rabbit P450 1A2. The extracted products were analyzed by liquid chromatography/negative electrosprayl selected ion monitoring mass spectrometry ( (m/z ϭ 179), are consistent with 12-HHT as the parent ion (Fig. 5, inset) . Finally, spectral analysis of incubation mixtures containing PGH 2 and rabbit P450 1A2 indicated the formation of a product with absorbance maxima at 234 and 268 nm (data not shown). These absorbance maxima are due to the conjugated diene of HHT and the enolate of MDA, respectively.
Comparison of P450 Catalytic Activity-These results indicated that microsomal P450 and purified P450 3A4 could convert PGH 2 to HHT and MDA. To explore the enzyme specificity of this conversion, several purified P450s were incubated with PGH 2 . We developed a spectrophotometric assay by monitoring the appearance of MDA at 267 nm that enabled us to observe continuously the conversion of PGH 2 to HHT and MDA (Fig. 6 ) (53). Reactions were conducted at 50 M PGH 2 . There was wide variation in the HHT/MDA synthase activity of different human P450s (Table I ). The activity of human P450 3A4 was about 10-fold greater than human P450 2E1, which in turn was 70% greater than human P450 1A2. There was also considerable interspecies variation in catalytic activities of P450 1A2 homologs (rabbit Ͼ rat Ͼ human). Boiling enzyme solutions prior to incubation decreased HHT/MDA synthase activity 5-fold, indicating that intact protein structure is required (data not shown). P450s-P450 substrates and inhibitors typically induce spectral shifts on binding to the resting enzyme in the absence of NADPH ϩ . Because PGH 2 is unstable and is converted quickly to a different product even in the absence of NADPH ϩ , we used stable cycloether analogs to probe the binding interaction attached to the heme site (Fig. 7) . U-44069 contains the ether oxygen attached to C-9, whereas the ether oxygen is attached to C-11 in U-46619. Incubation of U-44069 with rabbit P450 1A2 induced a reverse type 1 difference spectrum that exhibited a minimum at 386 nm and a maximum at 420 nm (Fig. 7a) . In contrast, U-46619 induced a type 1 spectrum with a minimum at 420 nm and a maximum at 386 nm at the same concentration (Fig. 7b) . The concentration dependence of U-44069 binding to rabbit P450 1A2 (Fig. 7c, open squares) exhibited saturation behavior with a K s of 200 Ϯ 20 M. The concentration dependence of U-46619 exhibited a biphasic character with a type 1 spectrum at low concentrations (K s of 300 Ϯ 500 M) and a reverse type 1 spectrum at higher concentrations (K s of 900 Ϯ 1300 M).
Binding of Stable Oxabicycloheptane Analogs of PGH 2 to
Human P450 3A4, which has an HHT/MDA synthase activity similar to rabbit 1A2 (Table I) , bound both PGH 2 analogs in a manner that produced type 1 spectral changes. Similar binding affinities were exhibited (K s ϭ 240 Ϯ 20 M, U-44069; K s ϭ 130 Ϯ 10 M, U-46619). Rat P450 2B1, which had 10-fold lower HHT synthase activity (Table I) , bound both analogs more weakly in a manner that produced reverse type 1 spectral changes (K s ϭ 1230 Ϯ 40 M, U-44069; K s ϭ 890 Ϯ 90 M, U-46619). These data indicate that HHT/MDA synthase activities correlate with PGH 2 analog binding affinities in the three enzymes tested. The P450s with higher HHT/MDA synthase activities, viz. human P450 3A4 and rabbit P450 1A2, bound at least one of the PGH 2 analogs with a K s of less than 200 M, and rat P450 2B1 that had lower HHT/MDA synthase activity bound both analogs with K s values close to 1 mM.
DISCUSSION
During development of certain malignancies, there is increased expression of COX-2, which leads to increased production of PGH 2 . There is also an increased expression of xenobiotic-metabolizing P450s. The present results show that several of these P450s catalyze the conversion of PGH 2 to HHT and the mutagen, MDA. Human liver microsomes have an HHT/MDA synthase activity that can be inhibited by P450 inhibitors. Recombinant and purified P450s also have HHT/MDA synthase activity, but other heme proteins do not. Both the HHT/ MDA synthase activity of xenobiotic-metabolizing P450s and the ability of stable PGH 2 analogs to bind to the active site varies widely between enzymes. These results suggest that aberrant expression of COX-2 and certain P450s in pre-malignant cells could lead to the stepwise conversion of arachidonic acid into a mutagen that can damage cellular DNA.
Stable Analog Binding-The binding spectra of the oxabicycloheptane analogs (U-44069 and U-46619) suggest a specific interaction with the enzyme-binding site of rabbit P450 1A2 (Fig. 7) . Reverse type 1 spectra are typical of oxygen ligands binding to the heme iron, and type 1 spectra are indicative of hydrophobic substrates displacing a weak oxygen ligand such as water or a hydroxyl group from the coordination site. In the case of rabbit P450 1A2, the reverse type I spectrum observed with U-44069, which has an ether oxygen attached to C-9, is consistent with the oxygen ligand interacting with the heme iron. On the other hand, if U-46619 binds in the same conformation, the C-9 substituent directed toward the heme iron would be a methylene group. This methylene could displace any weak endogenous oxygen ligand and produce the type 1 spectrum that was observed in Fig. 7b . At higher concentrations, U-46619 could bind in an alternate conformation allowing the C-11 ether oxygen to interact with the heme iron and FIG. 6 . Spectrophotometric monitoring of MDA formation from PGH 2 . PGH 2 (50 M) was incubated with 0.25 M rabbit P450 1A2 in 300 mM potassium phosphate, pH 7.4, and the absorbance at 268 nm was followed over time. The initial rate was estimated from the slope of a tangent to the first 10 s of the curve. produce the reverse type 1 spectrum that was observed in Fig.  7c . However, human P450 3A4 bound both PGH 2 analogs similarly which is consistent with its larger substrate-binding site (55) . Unlike thromboxane synthase, which coordinates to the C-9 oxygen, or prostacyclin synthase, which coordinates to the C-11 oxygen (22), we propose that most of the xenobiotic-metabolizing P450s bind PGH 2 in either conformation to catalyze O-O bond scission.
Relative Activities of P450s-The identification of HHT/MDA synthase activity in human liver microsomes extends the observation by Hecker and Ullrich (22) that rat liver microsomes and the bacterial enzyme, P450 CAM , convert PGH 2 to predominantly HHT. The use of purified P450s allowed comparison of relative catalytic activities directly. The greater than 10-fold variation in the HHT/MDA synthase activity of different P450s indicates that the binding sites of these enzymes can accommodate PGH 2 to differing degrees. The most active human P450 tested was 3A4 with an activity of 10 min Ϫ1 at 50 M PGH 2 . The calculated activity of thromboxane synthase at the same substrate concentration would be 1142 min Ϫ1 . This difference can be readily explained by the preferred substrates of these enzymes. The active site of thromboxane synthase is optimized for PGH 2 metabolism, whereas the xenobiotic-metabolizing P450s are notably promiscuous.
By using site-directed mutagenesis Wang and co-workers (56) identified several residues important for thromboxane synthase activity. Ala-408 and Arg-413 were absolutely required for production of thromboxane, but the mutations did not convert thromboxane synthase into an efficient HHT/MDA synthase (56) .
The HHT/MDA synthase activity of P450s need not be related to a high affinity binding site. The fact that a broad range of P450s can catalyze this reaction suggests that the structural requirement for HHT/MDA synthase activity is a relatively hydrophobic, open binding pocket with a P450-like heme to facilitate homolytic cleavage of the O-O bond (22) .
HHT/MDA Synthase in Cells-Given the fact that thromboxane synthase has higher HHT/MDA synthase than any other P450 tested, it is important to consider its expression pattern. Thromboxane synthase is expressed in colon tissue at levels similar to platelets (57), but immunohistochemistry experiments have shown that the expression is actually limited to the macrophage-like histiocytes (58) . In contrast to thromboxane synthase, P450s 1A and 3A are localized to the colonic mucosal epithelial cells that are the actual precursors of colorectal cancers (37) . The relative importance of tissue macrophage-produced MDA compared with colonic mucosa-produced MDA remains to be tested.
Although the HHT/MDA synthase activity of the xenobioticmetabolizing P450s is low compared with thromboxane synthase, cell culture experiments indicate that co-induction of COX-2 and a P450 may increase HHT/MDA production in vivo. When Hepa-1 cells were treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin, an inducer of both COX-2 and P450 1A1, HHT accounted for nearly 40% of the arachidonic acid metabolites (40) . In contrast, Hepa-1-derived cells null for P450 1A1 produced half as much HHT but four times as much PGF 2␣ (40) . It is clear that levels of a P450 expressed from genomic copies using an endogenous promoter are sufficient to shift dramatically the PGH 2 metabolite spectrum from prostanoids to HHT and MDA. This may be especially important in tissues where COX-2 is aberrantly expressed and the normal PGH 2 -converting enzymes are comparatively underexpressed.
Conclusion-We have shown that a range of xenobiotic-metabolizing P450s can convert the intermediate in prostaglandin biosynthesis, PGH 2 , to an unsaturated fatty acid and the mutagen MDA. Future studies need to address whether increased COX-2 and P450 expression in developing cancers correlates with increased DNA damage by MDA-DNA adducts in order to assess to the relative importance of accelerated DNA damage by the mechanism proposed here.
